Advantages in Efficacy and Delivery Will Make Qnexa the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources
WALTHAM, Mass., June 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug that is more effective than Roche's Xenical at inducing weight loss would earn a 40 percent patient share in the obesity drug market, according to surveyed primary care physicians. Although other efficacy measures-such as the effect on weight maintenance-are also important to prescribers, the biggest unmet need within this indication is a therapy that can consistently induce more than ten percent weight loss. The Food and Drug Administration currently requires that a drug elicit between five and ten percent weight loss to get approval.
The new report entitled Obesity: Current Pipeline Falls Short of Physicians' Expectations for Efficacy and Safety finds that Vivus's Qnexa will become Decision Resources' proprietary clinical gold standard by 2011 due to its competitive advantages in efficacy and delivery over the 2006 gold standard, Xenical. By 2016 however, Orexigen's Empatic will supersede Qnexa due to its advantage in safety. Both Empatic and Qnexa are fixed dose combinations of currently marketed central nervous system agents used for indications like epilepsy, alcohol dependence and depression.
"Phase II clinical trial data revealed that Qnexa caused a greater overall weight reduction compared with pooled data for Xenical after a 24-week treatment period," said Donny Wong, Ph.D., principal analyst at Decision Resources. "According to physicians we surveyed, Empatic's overall score for safety and tolerability is better, based on the perception that this combination agent is more conducive to longer-term treatment."
About the Report
Obesity: Current Pipeline Falls Short of Physicians' Expectations for Efficacy and Safety is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a world leader
in market research publications, advisory services, and consulting designed
to help clients shape strategy, allocate resources, and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
|SOURCE Decision Resources, Inc.|
Copyright©2008 PR Newswire.
All rights reserved